Suppr超能文献

芬太尼及其新型衍生物的临床药代动力学

Clinical pharmacokinetics of fentanyl and its newer derivatives.

作者信息

Mather L E

出版信息

Clin Pharmacokinet. 1983 Sep-Oct;8(5):422-46. doi: 10.2165/00003088-198308050-00004.

Abstract

Fentanyl, a synthetic opiate with a (clinical) potency of 50 to 100 times that of morphine, was introduced into clinical practice in the early 1960s. Usually administered by single intravenous doses, it developed a reputation for having a short duration of action and it was assumed that this was a consequence of rapid removal from the body. However, as clinical experience increased, it was realised that administration of multiple doses or large doses during narcotic-based anaesthesia sometimes led to delayed recovery and prolonged respiratory depression, suggesting that the duration of action was limited by redistribution within the body rather than removal from the body. Recent developments in analytical techniques have allowed pharmacokinetic studies and these have confirmed this opinion; fentanyl is rightly regarded as having a redistribution-limited duration of action after single or infrequent doses (analogous to thiopentone). However, the magnitude of the pharmacokinetic constants reported for fentanyl are remarkably inconsistent even in healthy volunteers, for reasons apparently only explainable by assay differences. Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min. Renal excretion accounts for up to 10% of the dose; the remainder of the clearance would appear to be predominantly hepatic, but with contributions from other tissues. Continued clinical developments of narcotic-based anaesthetic techniques have resulted in high doses of narcotic being used, with oxygen, as the sole anaesthetic agents. At present these techniques are usually based on fentanyl, and the technique is frequently called 'stress-free anaesthesia' because of the effects in obtunding the 'stress response' caused by surgery (elevation of plasma concentrations of cortisol, glucose, ADH, etc. in the intra- and post-operative period) and the lack of deleterious effects on the cardiovascular system.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

芬太尼是一种合成阿片类药物,其(临床)效力是吗啡的50至100倍,于20世纪60年代初被引入临床实践。它通常通过单次静脉注射给药,因作用持续时间短而闻名,人们认为这是其从体内快速清除的结果。然而,随着临床经验的增加,人们意识到在基于麻醉剂的麻醉过程中多次给药或大剂量给药有时会导致恢复延迟和呼吸抑制延长,这表明作用持续时间受体内重新分布的限制而非从体内清除的限制。分析技术的最新发展使得进行药代动力学研究成为可能,这些研究证实了这一观点;单次或不频繁给药后,芬太尼的作用持续时间受重新分布限制是合理的(类似于硫喷妥钠)。然而,即使在健康志愿者中,报道的芬太尼药代动力学常数的大小也显著不一致,原因显然只能用检测差异来解释。因此,表观分布容积(面积)的估计值范围从约60L到超过300L,终末半衰期的估计值范围从约1.5至6小时(老年患者为15小时),全身清除率范围从0.4至超过1.5L/分钟。肾排泄占剂量的比例高达10%;清除的其余部分似乎主要是肝脏清除,但其他组织也有贡献。基于麻醉剂的麻醉技术的持续临床发展导致高剂量麻醉剂与氧气一起作为唯一的麻醉剂使用。目前这些技术通常基于芬太尼,由于其对手术引起的“应激反应”(手术中和术后血浆皮质醇、葡萄糖、抗利尿激素等浓度升高)有抑制作用且对心血管系统无有害影响,该技术常被称为“无应激麻醉”。(摘要截取自400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验